Aragen, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced two senior level appointments. Dr. Manjunath Ramarao has been appointed as the Chief Scientific Officer (CSO) and Executive Vice President, Inte... Read more
Key Financial Highlights: Full-year net sales increased to €21.2 billion (organically: +2.0%) EBITDA pre rose to €6.1 billion (organically: +6.9%) Strong fourth quarter: Net sales up 3.8% organically year-on-year, EBITDA pre ... Read more
Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billion Fourth Quarter 2024 Net Loss of $31.3 million, decrease in Net Loss of 37% versus prior year Fourth Quarter 2024 Adjusted EBITDA of $21.0 milli... Read more
Artificial intelligence is reshaping oncology, and ImpriMed is at the forefront of this transformation. With its AI-powered Personalized Prediction Profile (PPP), ImpriMed is redefining cancer treatment for pets by predicting drug responses with un... Read more
Paratek Pharmaceuticals and Optinose, Inc. announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, including its approved product XHANCE® (fluticasone propionate). The transaction value is up... Read more
Sarepta Therapeutics, Inc. the leader in precision genetic medicine for rare diseases, announced that it has closed on a $600 million senior secured revolving credit facility with a bank syndicate. "Sarepta's financial strength and the pos... Read more
Aragen, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced two senior level appointments. Dr. Manjunath Ramarao has been appointed as the Chief Scientific Officer (CSO) and Executive Vice President, Inte... Read more
CordenPharma is making a record investment of >€1 billion over the next 3 years in building and / or expanding small, medium, and large peptide manufacturing facilities across Europe and the US. In Switzerland, Cor... Read more
© 2025 Biopharma Boardroom. All Rights Reserved.
